Sara Helene Shanti


Related Content

  • Loyola University Chicago School of Law, JD, 2009
  • University of Michigan, BS, Biology, 2002
  • Illinois

Sara joins the firm as an associate practicing in the healthcare department. She represents healthcare providers as well as healthcare technology and life sciences companies in regulatory and transactional matters. Sara’s practice maintains a focus on data privacy and security, counseling clients on various digital health matters, including gamification and telemedicine. 

Sara’s experience includes advising clients on compliant implementation of patient-facing health applications, data transfers across multi-national borders, and security incident response procedures. Her experience extends to transactional matters, medical staff relationships, and minor patient rights.

Prior to entering private practice, Sara worked for the United States Department of Health and Human Services, Office for Civil Rights (OCR). Before receiving her law degree, Sara applied her degree in biology to medical research projects, concentrating on epigenetics and immunologic responses in cancer patients.

My practice is focused on meeting the legal challenges that face health providers and health technologists, so that they can fully achieve their incredible missions of care and improved health.

Sara Shanti
T: +1 312 849 8143F: +1 312 920 614377 West Wacker Drive
Suite 4100
Chicago, IL 60601-1818

Representation of numerous private equity firms in connection with transactions involving healthcare companies.

Representation of a private equity firm in its acquisition of a company that delivers professional in-home nursing care to qualified beneficiaries.

Co-author, collaboration with Cleveland Clinic, Impact of the European Union’s Recently Enacted General Data Protection Regulation (“GDPR”) on U.S. Academic Medical Centers, American Health Lawyers Association E-Alert, May 2016
Co-author, Impact of the European Union's Approved General Data Protection Regulation On Scientific Research and Secondary Uses of Personal Data, Bloomberg BNA Medical Research Law & Policy Report, February 2016
Quoted, EMTALA Deficiencies Rise, But Why, Healthcare Risk Management, June 2014
Quoted, States Say EMTALA Doesn’t Stop with Admission, Healthcare Risk Management, June 2014
Contributor, Meaningful Responses to Meaningful Use Audits, The Advisory Board Company – General Counsel Agenda, June 2014
Co-author, How to Handle a Meaningful Use Audit, AGA Quarterly - American Gastroenterological Association, April 2014
Co-author, WellPoint Settlement: A Warning for HIPAA-Covered Entities, Law360, August 2013
Co-author, Feasibility of Conditioning with Thymoglobulin and Reduced Intensity Total Body Irradiation to Reduce Acute Graft v. Host Disease in Recipients of Allogeneic Stem Cell Transplantation, BMT, 2008
Co-author, Separating Graft vs. Tumor from Graft vs. Host Responses in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation; Reigning in Adoptive Immunity, Blood, 2006
Speaker, "Group Health Plan HIPAA Compliance Trainings," November-December 2016
Speaker, "HIPAA Compliance Demystified, MATTER," Chicago Healthcare Startup Incubator Workshop, May 2015
Panelist, International Device and Pharmaceutical Privacy Consortia, 2011-2015
Panelist, Illinois Association of Health Care Attorneys, 2012-2014
Speaker, "HIPAA Omnibus Rule Webcast: New Regulation Considerations," HealthITSecurity, June 2014
Speaker, "Medical Records Law," Seminar, August 2012
Speaker, "Public outreach engagements and trainings," representing HHS/OCR, 2009-2011
HIPAA Breach Reporting: 2017 Trends and Mends, Password Protected, January 19, 2018
Big Brother is a Pill: Digital Tracking Drugs, Password Protected, January 11, 2018